<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690104</url>
  </required_header>
  <id_info>
    <org_study_id>Rifa-BP</org_study_id>
    <secondary_id>2011-005522-22</secondary_id>
    <nct_id>NCT01690104</nct_id>
  </id_info>
  <brief_title>The Effect of PXR Activation on Blood Pressure Regulation</brief_title>
  <official_title>The Effect of PXR Activation on Blood Pressure Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are investigating the effects of pregnane X receptor (PXR) activation on the regulation of
      blood pressure in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR
      activator) and placebo will be given for a week to volunteers and blood pressure is measured
      24 hours using an ambulatory blood pressure monitor. Blood pressure regulating hormones will
      be measured in blood. Our hypothesis is that PXR is involved in the regulation of blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic ambulatory blood pressure</measure>
    <time_frame>On day 8 of each arm</time_frame>
    <description>Systolic blood pressure measured with ambulatory blood pressure monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic ambulatory blood pressure</measure>
    <time_frame>On day 8 of each arm</time_frame>
    <description>Diastolic blood pressure measured with ambulatory blood pressure monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>On day 9 of each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (ambulatory)</measure>
    <time_frame>On day 8 of each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin activity</measure>
    <time_frame>On day 9 of each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aldosterone</measure>
    <time_frame>On day 9 of each arm</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Blood Pressure Regulation</condition>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampicin 600 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <arm_group_label>Rifampicin</arm_group_label>
    <other_name>Rimapen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  BMI 19-30 kg/m2

          -  Age 18-40 years

          -  Systolic blood pressure 95 - 140 mmHg

        Exclusion Criteria:

          -  Any continuous medication

          -  Any significant medical condition as judged by the study physician

          -  Diastolic blood pressure over 90 mmHg

          -  Sensitivity to rifampicin

          -  Pregnancy and lactation

          -  Difficult venipuncture

          -  Abuse of alcohol or medications, or drug use.

          -  Participation in other trial with medications in previous 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne Hukkanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampicin</keyword>
  <keyword>pregnane X receptor</keyword>
  <keyword>blood pressure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

